Fox Chase Cancer Center | Strategic Alliance Partners

August 15, 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

August 01, 2017

Alexander Kutikov, MD, has been appointed the new chief of the Division of Urologic Oncology at Fox Chase Cancer Center.

July 27, 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

July 27, 2017

Elizabeth Plimack, MD, recaps recent advances in bladder cancer and discusses the need for diverse approaches to further improve patient outcomes.

January 20, 2017

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

October 06, 2016

Lori Rink, PhD, discusses the groundbreaking impact of imatinib (Gleevec) in gastrointestinal stromal tumors, the heterogeneity of the disease and its impact on personalizing treatment, and emerging therapies in the field.

October 05, 2016

Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.

September 21, 2016

Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.

July 21, 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma.

July 05, 2016

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.

June 29, 2016

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

June 10, 2016

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.

April 02, 2016

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

December 21, 2015

Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences

October 20, 2015

Medical oncologist Lori J. Goldstein, MD, from Fox Chase Cancer Center, have been looking at reparixin, an investigational study drug that targets breast cancer stem cells.

August 20, 2015

Fox Chase Cancer Center's breast cancer program has earned full accreditation for the third time from The National Accreditation Program for Breast Centers.

July 02, 2015

Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

April 29, 2015

Although patients with invasive lobular carcinoma are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.

February 05, 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

February 04, 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.